FDA issues another safety alert related to fecal transplants, as data suggest coronavirus lingers in poop
Since 2013, the FDA has implemented a policy of “enforcement discretion” regarding fecal microbiota transplants (FMT) to treat refractory C. diff: While biopharma companies work on developing standardized products, physicians can conduct FMT’s after securing reasonable consent from patients. But since last summer, a handful of safety issues have caused a stir in the field.
Earlier this week, the FDA issued a safety alert highlighting the risk of potential transmission of the new coronavirus from fecal matter derived from donors used in FMT, and said that additional safety measures are necessary.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.